Molecular Templates, Inc. (MTEM): Price and Financial Metrics

Molecular Templates, Inc. (MTEM): $4.01

-0.12 (-2.91%)

POWR Rating

Component Grades














  • MTEM scores best on the Value dimension, with a Value rank ahead of 66.61% of US stocks.
  • MTEM's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • MTEM ranks lowest in Momentum; there it ranks in the 4th percentile.

MTEM Stock Summary

  • With a year-over-year growth in debt of 64.68%, Molecular Templates Inc's debt growth rate surpasses 87.48% of about US stocks.
  • In terms of volatility of its share price, MTEM is more volatile than 88.48% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MTEM comes in at -39.85% -- higher than that of merely 8.39% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Molecular Templates Inc, a group of peers worth examining would be KLDO, MIST, RNA, SRRK, and RGNX.
  • Visit MTEM's SEC page to see the company's official filings. To visit the company's web site, go to

MTEM Valuation Summary

  • MTEM's price/sales ratio is 14; this is 268.42% higher than that of the median Healthcare stock.
  • Over the past 202 months, MTEM's price/sales ratio has gone NA NA.
  • MTEM's price/sales ratio has moved NA NA over the prior 202 months.

Below are key valuation metrics over time for MTEM.

Stock Date P/S P/B P/E EV/EBIT
MTEM 2021-08-31 14.0 3.8 -3.9 -4
MTEM 2021-08-30 13.9 3.7 -3.9 -4
MTEM 2021-08-27 13.8 3.7 -3.8 -4
MTEM 2021-08-26 13.8 3.7 -3.9 -4
MTEM 2021-08-25 14.0 3.7 -3.9 -4
MTEM 2021-08-24 14.0 3.8 -3.9 -4

MTEM Growth Metrics

  • The 5 year price growth rate now stands at 405.7%.
  • Its 2 year revenue growth rate is now at 291.98%.
  • The 3 year net cashflow from operations growth rate now stands at 85.58%.
MTEM's revenue has moved up $3,365,000 over the prior 15 months.

The table below shows MTEM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 24.23 -29.432 -101.211
2021-06-30 26.149 -24.44 -94.049
2021-03-31 17.924 -23.434 -109.676
2020-12-31 18.845 -83.797 -104.916
2020-09-30 21.545 -48.263 -92.352
2020-06-30 20.865 -44.839 -107.346

MTEM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MTEM has a Quality Grade of C, ranking ahead of 37.75% of graded US stocks.
  • MTEM's asset turnover comes in at 0.13 -- ranking 237th of 681 Pharmaceutical Products stocks.
  • AGEN, ARDX, and LGND are the stocks whose asset turnover ratios are most correlated with MTEM.

The table below shows MTEM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.130 1 -0.688
2021-03-31 0.102 1 -1.004
2020-12-31 0.123 1 -0.976
2020-09-30 0.133 1 -0.940
2020-06-30 0.146 1 -1.283
2020-03-31 0.139 1 -1.005

MTEM Price Target

For more insight on analysts targets of MTEM, see our MTEM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.43 Average Broker Recommendation 1.33 (Strong Buy)

MTEM Stock Price Chart Interactive Chart >

Price chart for MTEM

MTEM Price/Volume Stats

Current price $4.01 52-week high $15.19
Prev. close $4.13 52-week low $3.93
Day low $3.93 Volume 1,041,600
Day high $4.22 Avg. volume 333,644
50-day MA $5.80 Dividend yield N/A
200-day MA $7.93 Market Cap 225.78M

Molecular Templates, Inc. (MTEM) Company Bio

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.

MTEM Latest News Stream

Event/Time News Detail
Loading, please wait...

MTEM Latest Social Stream

Loading social stream, please wait...

View Full MTEM Social Stream

Latest MTEM News From Around the Web

Below are the latest news stories about Molecular Templates Inc that investors may wish to consider to help them evaluate MTEM as an investment opportunity.

Zacks: Analysts Anticipate Molecular Templates, Inc. (NASDAQ:MTEM) Will Announce Earnings of -$0.30 Per Share

Wall Street analysts expect that Molecular Templates, Inc. (NASDAQ:MTEM) will announce earnings of ($0.30) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Molecular Templates earnings. The lowest EPS estimate is ($0.71) and the highest is $0.08. Molecular Templates posted earnings per share of ($0.53) during the same []

Dakota Financial News | November 22, 2021

FY2021 Earnings Estimate for Molecular Templates, Inc. Issued By Jefferies Financial Group (NASDAQ:MTEM)

Molecular Templates, Inc. (NASDAQ:MTEM) Investment analysts at Jefferies Financial Group decreased their FY2021 earnings estimates for Molecular Templates in a report issued on Monday, November 15th. Jefferies Financial Group analyst R. Song now expects that the biotechnology company will earn ($1.17) per share for the year, down from their prior estimate of ($0.71). Jefferies []

Transcript Daily | November 20, 2021

Molecular Templates Inc. (NASDAQ: MTEM) Has Succeeded In Generating Interest In 2021, The Stock Is Down -53.67% Year-To-Date

Molecular Templates Inc. (NASDAQ:MTEM)s traded shares stood at 0.37 million during the last session, with the companys beta value hitting 1.06. At the close of trading, the stocks price was $4.35, to imply a decrease of -2.90% or -$0.13 in intraday trading. The MTEM shares 52-week high remains $15.19, putting it -249.2% down since that Molecular Templates Inc. (NASDAQ: MTEM) Has Succeeded In Generating Interest In 2021, The Stock Is Down -53.67% Year-To-Date Read More »

Marketing Sentinel | November 20, 2021

Molecular Templates, Inc. Forecasted to Post FY2021 Earnings of ($1.80) Per Share (NASDAQ:MTEM)

Molecular Templates, Inc. (NASDAQ:MTEM) Stock analysts at Oppenheimer reduced their FY2021 earnings per share (EPS) estimates for shares of Molecular Templates in a report issued on Monday, November 15th. Oppenheimer analyst K. Degeeter now forecasts that the biotechnology company will post earnings per share of ($1.80) for the year, down from their prior forecast []

Dakota Financial News | November 19, 2021

Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402

AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.

Intrado Digital Media | November 18, 2021

Read More 'MTEM' Stories Here

MTEM Price Returns

1-mo -27.62%
3-mo -38.31%
6-mo -53.96%
1-year -54.74%
3-year -22.14%
5-year -24.05%
YTD -57.29%
2020 -32.86%
2019 246.16%
2018 -59.68%
2017 107.02%
2016 -8.33%

Continue Researching MTEM

Want to see what other sources are saying about Molecular Templates Inc's financials and stock price? Try the links below:

Molecular Templates Inc (MTEM) Stock Price | Nasdaq
Molecular Templates Inc (MTEM) Stock Quote, History and News - Yahoo Finance
Molecular Templates Inc (MTEM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6929 seconds.